De La Rue Sarah A, Bickston Stephen J
Digestive Health Center of Excellence, University of Virginia Health System, Charlottesville, Virginia, USA.
Curr Opin Gastroenterol. 2006 Jul;22(4):365-9. doi: 10.1097/01.mog.0000231809.10773.c7.
Evidence-based medicine is an increasingly important tool to aid the clinician in the treatment of patients. This is particularly true for diseases such as the inflammatory bowel diseases, for which the pathogenesis is unknown and an extensive range of treatment options is available. High quality data may not be available for all decisions, but it is essential that clinicians are aware of well-grounded data that are available.
The body of data supporting the use of biological therapies in inflammatory bowel disease continues to grow and diversify. Regulatory requirements and academic expectations are evolutionary forces that are resulting in continuous improvement in the quality of studies.
This review will update the reader on several significant analyses that have been published recently. It is intended to raise awareness of the data, helping clinicians to evaluate new treatments and to revisit older treatments with a critical eye.
循证医学是帮助临床医生治疗患者的一项日益重要的工具。对于诸如炎症性肠病这类发病机制不明且有广泛治疗选择的疾病而言尤其如此。并非所有决策都能获取高质量数据，但临床医生了解现有可靠数据至关重要。
支持在炎症性肠病中使用生物疗法的数据量持续增长且日益多样化。监管要求和学术期望是推动研究质量不断提高的进化力量。
本综述将向读者介绍近期发表的几项重要分析。旨在提高对这些数据的认识，帮助临床医生评估新疗法并以批判性眼光重新审视旧疗法。
